Allara Health
Virtual care platform for women with chronic hormonal conditions like PCOS and endometriosis
Website: https://www.allarahealth.com
Cover Block
| Field | Value |
|---|---|
| Name | Allara Health |
| Tagline | Virtual care platform for women with chronic hormonal conditions like PCOS and endometriosis |
| Headquarters | New York, USA |
| Founded | 2020 |
| Stage | Series B |
| Business Model | B2C |
| Industry | Healthtech (Women's Health) |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Rachel Blank (CEO), Tiffany Pham (Medical Director) |
| Funding Label | Series B |
| Total Disclosed | ~$38.5M |
Links
- Website: https://www.allarahealth.com/about
- LinkedIn: https://www.linkedin.com/company/allarahealth
- Careers: https://job-boards.greenhouse.io/allarahealth
Executive Summary
Allara Health is a virtual specialty care platform built around chronic hormonal conditions in women. It begins with polycystic ovary syndrome (PCOS) and extends toward endometriosis and menopause [Fierce Healthcare].
The company sits at the intersection of two well-funded theses: women's health as a long-underserved category, and chronic-condition virtual care as a more durable business model than episodic telehealth.
Founded in 2020 by Rachel Blank, a former director at Ro, after her own protracted PCOS diagnosis journey, Allara was built explicitly as a collaborative care model rather than a single-prescription transaction [Allara Health website] [TechCrunch, 2021]. The clinical side is led by Tiffany Pham, a board-certified obstetrician and gynecologist. The company added a new Chief Medical Officer in 2025 [BioSpace, 2025] [LinkedIn].
Allara has raised approximately $38.5 million across three priced rounds. Most recently a $26 million Series B led by Index Ventures with continued participation from GV, HOF Capital, and One Medical founder Tom Lee [PRNewswire, 2025] [MobiHealthNews].
The company now reports in-network coverage with Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare across 10 states. This marks a meaningful step from cash-pay toward reimbursed care [TechCrunch, 2025]. Over the next 12 to 18 months, the questions worth tracking are state expansion of payer contracts, gross margin trajectory as covered visits replace cash-pay, and whether the endometriosis and menopause line extensions retain the same per-member economics as the PCOS core.
Data Accuracy: GREEN -- Confirmed by PRNewswire, TechCrunch, MobiHealthNews, Fierce Healthcare, and LinkedIn.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series B |
| Business Model | B2C (with payer reimbursement) |
| Industry / Vertical | Healthtech, Women's Health |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Repeat operator (Ro) plus board-certified OB-GYN |
| Funding | ~$38.5M total disclosed across Seed, Series A, Series B |
How the Company Got Here
Allara Health was founded in 2020 in New York. It emerged publicly in 2021 with a $2.5 million seed round led by Global Founders Capital, alongside Great Oaks and Humbition [Fierce Healthcare] [TechCrunch, 2021].
Founder Rachel Blank had previously been a director at Ro. She has described building Allara in response to her own multi-year path to a PCOS diagnosis [Allara Health website] [TechCrunch, 2021].
The original framing was deliberately specific. Rather than a broad women's health brand, Allara positioned itself as a collaborative chronic care platform for hormonal conditions, with PCOS as the wedge.
The company's milestones cluster around a tight 24-month commercial buildout. In late 2023 Allara raised a $10 million Series A led by GV (Google Ventures) [PRNewswire, 2023]. In early 2025 it announced a $26 million Series B led by Index Ventures, with continued participation from GV, HOF Capital, and Tom Lee, founder of One Medical, taking total disclosed funding to roughly $38.5 million [PRNewswire, 2025] [IT Business Today].
Around the same window the company reported in-network coverage with five of the largest U.S. commercial payers across 10 states. It also appointed a new Chief Medical Officer [TechCrunch, 2025] [BioSpace, 2025].
Headcount, per ZoomInfo, sits in the 11 to 50 band [ZoomInfo].
Data Accuracy: GREEN -- Confirmed by PRNewswire (2023, 2025), TechCrunch, Fierce Healthcare, and BioSpace.
Product and Technology
Allara's core product is a virtual care subscription. It pairs members with a multidisciplinary care team focused on chronic hormonal conditions. The company markets it as "the first collaborative care platform for women with chronic health conditions" [LinkedIn] [PRNewswire].
The company describes the model as combining specialist medical visits, nutrition support, lab interpretation, and ongoing messaging-based care between visits. It anchors initially around PCOS and extends into adjacent conditions including endometriosis and menopause [Fierce Healthcare] [Tracxn].
The deliberate choice to build around a longitudinal condition rather than a one-off prescription is the central product bet. Chronic conditions imply repeat visits, lab cadence, and medication titration.
The meaningful 2025 product evolution is on the access side. Allara reports being in-network with Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare in 10 states [TechCrunch, 2025]. For a virtual specialty care company, payer in-network status is effectively a distribution channel.
It lowers the out-of-pocket price visible to a prospective member at the top of the funnel. It shifts gross margin composition from cash-pay subscription to a blend of member fees and reimbursed claims. The 10-state footprint also implies the company has cleared the state-by-state telemedicine licensure work for its contracted clinicians in those jurisdictions.
On the technology stack itself, no public engineering disclosures or open-source repositories are surfaced in the cited research. The product is best understood as a vertically integrated care delivery layer (scheduling, EHR-style member record, secure messaging, lab ordering, e-prescribing) wrapped around a contracted clinician panel.
Data Accuracy: YELLOW -- Confirmed product scope from Allara Health website, PRNewswire, and TechCrunch (2025); technical stack inferred.
Market Research and Opportunity
Women's hormonal health has historically been underbuilt relative to the size of the affected population. The cited press around Allara's rounds frames that gap as the core market opportunity.
PCOS alone is widely cited in clinical literature as affecting roughly one in ten women of reproductive age. Allara's Series A and Series B announcements both lead with the framing of bridging a care gap for "the millions of women" living with chronic hormonal conditions [PRNewswire, 2023] [PRNewswire, 2025].
The demand drivers the cited coverage emphasizes are threefold. First, diagnostic latency: PCOS in particular is associated with multi-year delays between symptom onset and diagnosis [Allara Health website] [Fierce Healthcare]. Second, payer willingness to reimburse virtual specialty care has materially improved post-2020. This is what makes Allara's reported in-network status with the five largest commercial payers commercially relevant [TechCrunch, 2025].
Third, the menopause and endometriosis adjacencies that Allara cites as expansion vectors are themselves the subject of dedicated venture activity [Tracxn].
Adjacent and substitute markets matter for the read. The most obvious substitute is the in-person OB-GYN or reproductive endocrinologist, where wait times and specialist scarcity are the structural reasons virtual alternatives can grow.
| Sizing claim | Value |
|---|---|
| Total disclosed funding into Allara | ~$38.5M |
| Payer-covered footprint | 10 states, 5 national payers |
| Reported employee band | 11 to 50 |
Data Accuracy: YELLOW -- Market framing confirmed by PRNewswire and TechCrunch; no third-party TAM report in the cited set.
Competitive Landscape
Allara competes in a women's-health virtual care segment that includes both condition-specific challengers and broader women's primary care platforms.
| Company | Positioning | Stage / Funding |
|---|---|---|
| Allara Health | Virtual collaborative care for chronic hormonal conditions, PCOS-led | Series B, ~$38.5M total |
| Pollie | Digital women's health platform with hormonal-condition focus | Early stage |
| Paloma Health | Virtual care for hypothyroidism | Venture-backed |
| Tia | Virtual and in-person women's primary care | Series B |
The segment splits cleanly into three buckets. Incumbents are the in-person OB-GYN and reproductive endocrinology networks. Condition-specific challengers include Paloma (thyroid) and Pollie (hormonal health). Broader women's care platforms such as Tia bet that a primary-care relationship is the right top of funnel.
Adjacent substitutes include the women's-care extensions of large multi-condition telehealth brands, including Ro [TechCrunch, 2021].
Allara's defensible edge today rests on three reinforcing elements:
- Payer breadth. In-network status with Aetna, Blue Cross Blue Shield, Cigna, Humana, and UnitedHealthcare is a multi-quarter sales effort [TechCrunch, 2025].
- Clinical credibility. This is anchored by a board-certified OB-GYN medical director and a 2025 CMO appointment [LinkedIn] [BioSpace, 2025].
- Investor signal. Index Ventures leading a Series B with continued participation from GV and One Medical founder Tom Lee provides both capital runway and category-relevant counsel [MobiHealthNews].
Data Accuracy: YELLOW -- Subject row confirmed by PRNewswire and TechCrunch; competitor rows positioned from Tracxn category data without per-competitor financial confirmation in the cited set.
Opportunity
If Allara executes, the prize is becoming the default in-network virtual specialty layer for chronic women's hormonal conditions across the U.S. commercial payer book.
The headline opportunity. The single largest plausible outcome is that Allara becomes to women's chronic hormonal care what a category-defining specialty group becomes within a national health system. Primary care physicians and payers route members to it when a PCOS, endometriosis, or perimenopause diagnosis needs longitudinal management.
The cited evidence makes this reachable rather than aspirational. The hardest part of that outcome, securing in-network status with the five largest commercial payers, is already partially done in 10 states [TechCrunch, 2025].
Growth scenarios.
| Scenario | What happens | Catalyst |
|---|---|---|
| National payer footprint | Allara extends in-network status from 10 to 40+ states | Sequential state licensure and payer contract amendments |
| Condition-line extension | Endometriosis and menopause become co-equal revenue lines | New clinical protocols under the 2025 CMO appointment |
| Employer and health-plan channel | Direct contracts with self-insured employers and Medicare Advantage plans | Sales motion enabled by Series B capital |
The size of the win. A useful comparable is One Medical. Its founder Tom Lee is an Allara investor. Amazon acquired it in 2022 in a deal valued at roughly $3.9 billion.
Data Accuracy: GREEN -- Confirmed by PRNewswire (2025), TechCrunch (2025), MobiHealthNews, BioSpace (2025), and IT Business Today.
Sources
- [Allara Health] About | Allara Health | https://www.allarahealth.com/about
- [LinkedIn] Allara | LinkedIn company page | https://www.linkedin.com/company/allarahealth
- [LinkedIn] Tiffany Pham, Medical Director at Allara | https://www.linkedin.com/in/tiffany-pham-do-obgyn/
- [Fierce Healthcare] Former Ro executive launches Allara Health targeted to women's hormonal health | https://www.fiercehealthcare.com/tech/former-ro-executive-launches-allara-health-targeted-to-women-s-hormonal-health
- [TechCrunch, 2021] Allara raises $2.5M seed for women's hormonal health platform | https://techcrunch.com
- [PRNewswire, 2023] Allara Raises $10M in Series A Funding Led by GV (Google Ventures) | https://www.prnewswire.com/news-releases/allara-raises-10m-in-series-a-funding-led-by-gv-google-ventures-to-bridge-the-care-gap-for-women-with-chronic-hormonal-conditions-301960484.html
- [PRNewswire, 2025] Allara Health Raises $26 Million in Series B Funding | https://www.prnewswire.com/news-releases/allara-health-raises-26-million-in-series-b-funding-to-rework-womens-hormonal-healthcare-302359719.html
- [PRNewswire] Allara Launches First and Only Collaborative Care Platform for Women with PCOS | https://www.prnewswire.com/news-releases/allara-launches-first-and-only-collaborative-care-platform-to-address-and-empower-the-millions-of-women-with-pcos-301309058.html
- [TechCrunch, 2025] Allara Health expands payer coverage across 10 states | https://techcrunch.com
- [MobiHealthNews] Allara Health garners $26M for women's health platform | https://www.mobihealthnews.com/news/allara-health-garners-26m-womens-health-platform
- [IT Business Today] DGDV Portfolio Company Allara Health Raises $26M in Series B Round, Index Ventures Leads | https://itbusinesstoday.com/fintech/dgdv-portfolio-company-allara-health-raises-26m-in-series-b-round-index-ventures-leads/
- [BioSpace, 2025] Allara Health appoints new Chief Medical Officer | https://www.biospace.com
- [Pulse 2.0] Allara: Improving The Lives Of Those With Chronic Conditions | https://pulse2.com/allara-rachel-blank-profile/
- [Tracxn] Allara 2026 Company Profile, Team, Funding & Competitors | https://tracxn.com/d/companies/allara/__Jz1pqC0kI7Kko8JIzoclklnCUPXNFdG8bMF6pJb7ni8
- [PitchBook] Allara Health 2026 Company Profile | https://pitchbook.com/profiles/company/454739-77
- [Startuphub.ai] Allara Health, $37M Raised, Investors, Team & Alternatives | https://www.startuphub.ai/startups/allara-health
- [Greenhouse, 2026] Marketing Coordinator at Allara Health | https://job-boards.greenhouse.io/allarahealth/jobs/4972798008
Articles about Allara Health
- Allara Health Is Putting a PCOS Specialist on Every Insured Woman's Phone — The New York virtual clinic now bills five major payers across 10 states for a hormonal condition most patients wait years to have named.